Phase 4
Completed N=184
Predictors of Response to Iron and Erythropoietin Stimulating Agents
Renal Failure Chronic · Anemia
Source: ClinicalTrials.gov NCT03658876 ↗
Enrolled (actual)
184
Serious AEs
20.7%
Results posted
Jul 2019
Primary outcomePrimary: Hemoglobin Incrementation — 61; 53 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment. A positive outcome following treatment was defined as an uptitration of haemoglobin by greater than 5g/l within 2 months. The study evaluated the participants response to treatment against the clinical and biochemical information collected prior to treatment being received.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hemoglobin Incrementation |
61; 53 | — |
Eligibility Criteria
Inclusion Criteria
- All prevalent haemodialysis patients, established for greater than 3 months
Exclusion Criteria
Inability to consent Bone marrow disorder Transfusion dependence Active bleeding Active infection Active malignancy Frail with either frequent hospital admissions or unable to follow trial protocol due to differing target haemoglobin
Data sourced from ClinicalTrials.gov (NCT03658876). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.